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DMBA = 7,12-dimethylbenz[a]anthracene; IL = interleukin; K14 = keratin 14; LFS = Li–Fraumeni syndrome; MMTV = mouse mammary tumor virus;
TP53 = human p53 tumor suppressor gene; Trp53 = mouse p53 tumor suppressor gene; WAP = whey acidic protein; WAP-DES = WAP-
des(1–3)insulin-like growth factor-I transgene.
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Introduction
The p53 tumor suppressor gene (TP53  in humans or
Trp53 in mice) is critical for inhibiting tumor development
in many tissues. This is evident in breast epithelium from
the high frequency of mutations in TP53  in sporadic
human breast cancers [1]. Consistent with this phenome-
non, germline mutations in p53 predispose women to
breast cancer. Li–Fraumeni syndrome (LFS) patients, of
whom approximately one-half carry mutations in one allele
of TP53 [2], suffer from a high frequency of breast cancer,
with early-onset breast cancer accounting for approxi-
mately one-half of the tumors observed in LFS women
[3,4]. Furthermore, even in the context of mutations in the
breast cancer susceptibility genes BRCA1 and BRCA2,
high rates of p53 mutation are found [5,6]. Thus, p53
appears to be a critical agent in the protection of the
breast epithelium against tumorigenesis.
The way in which p53 performs its tumor suppressor role
involves diverse cellular processes. The repertoire of p53
activities includes the regulation of the cell cycle, apoptosis,
senescence, facilitating DNA repair, and antagonizing
angiogenesis (Fig. 1). Many of these functions are mediated
by transcriptional activation of target genes by p53 [7],
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The human p53 tumor suppressor gene TP53  is mutated at a high frequency in sporadic breast
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regulation of p53 activity by hormones, of the effect of mouse strain and modifier genes on tumor
phenotype, and of the cooperation between p53 and other oncogenic pathways, chemical
carcinogens and hormonal stimulation in mammary tumorigenesis. Both p53 transgenic and knockout
mice are important in vivo tools for understanding breast cancer, and are yet to be exploited for
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such as the induction of cell-cycle arrest by transcriptional
activation of p21WAF1, a cyclin-dependent kinase inhibitor.
Other activities may involve the p53 protein more directly,
such as the 3′→5′ exonuclease activity of p53 that may
contribute to fidelity of DNA replication [8].
The p53 protein levels are normally very low, due to rapid
turnover, but in response to various stressful stimuli, such
as DNA damage or hypoxia, the p53 protein is stabilized
and activated to perform its functions. The regulation of
p53 stability and activity involves many proteins, such as
the antagonist MDM2 that binds the transactivation domain
and also targets p53 for ubiquitination and degradation, or
the kinases DNA-PK and ATM that phosphorylate p53 at
several of its many sites for post-translational modification
[9,10]. The overall p53 response of a cell thus depends on
the integration of the signals and activities of many different
mechanisms and proteins. The important consequences of
p53 activity, potentially cell death or tumor promotion,
require this fineness and multiplicity of controls.
With this level of control over p53 function, it is not sur-
prising that loss or mutation of one allele of p53 can have
serious consequences. This is the case in LFS patients,
who are susceptible to a wide range of tumor types in
addition to breast cancer [3,4]. In contrast with Knudson’s
two-hit hypothesis for tumor suppressor genes, however,
tumors can develop in Trp53+/– mice while still retaining a
functional wild-type Trp53 allele, indicating that p53 is
haploinsufficient for tumor suppression [11]. The reduc-
tion in p53 dosage that results from heterozygosity at the
genetic level has been shown in many mouse tissues to
result in an intermediate level of transcriptional activity,
growth control and apoptosis compared with wild-type
and Trp53–/– cells [12–14]. This may lead to the retention
of cells that have acquired further oncogenic mutations,
thus resulting in haploinsufficiency for tumor suppression.
The protection of the mammary epithelium against tumori-
genesis by p53 may thus involve many different
processes. While the fine details of mechanisms and regu-
lation are best addressed in highly manipulable in vitro
systems, the biological consequences of such findings
need to be verified in vivo where all the signals from the
whole tissue and whole animal are intact. Studies in trans-
genic and knockout mice on the role of p53 and other
molecules in breast cancer have therefore not focused on
detailed mechanisms, but have been aimed at mimicking
genetic susceptibility to breast cancer observed in
humans, and at demonstrating a functional role for molec-
ular lesions observed in end-stage human disease. While
Trp53 knockout mice have provided much insight into the
role of p53 in tumor suppression, tools that allow specific
modulation of the mammary gland have greatly enhanced,
and in some cases have been essential to, our under-
standing of the function of p53 and its interaction with
other molecules in protection against breast cancer.
Altering p53 function in the mouse mammary
gland
The function of p53 has been modified genetically in mice
in several ways (Table 1). Targeted disruption of the Trp53
gene has been performed by several groups [15–17]. This
process removes several exons from the endogenous
gene and results in the absence of p53 protein in all
tissues of the mouse throughout development and adult-
hood. Mice homozygous for the Trp53  null allele
(Trp53–/–) die at 4–6 months of age, primarily from lym-
phomas. Only on the BALB/c genetic background have
significant numbers of mammary tumors been observed in
Trp53+/– mice, mimicking LFS of humans [18].
To study gene function in a particular tissue without the
complication of death due to other tumor types (e.g. lym-
phomas) or embryonic lethality, tissue-specific deletion of
genes within the mammary glands has been achieved
using conditional knockouts [19,20]. In this system, the
gene to be deleted is modified by inserting recombination
sites (loxP or FRT) both sides of the gene, and it is intro-
duced into the mouse as a targeted insertion. This does
not alter gene function until a recombinase is expressed
that recombines the chromosome at the two inserted
recombination sites, thus deleting the gene segment
between them. Tissue-specific expression of the recombi-
nase (Cre for loxP sites, and Flp for FRT sites) achieves
the tissue-specific gene deletion.
Figure 1
Activation of p53 and responses. The p53 protein can exist in multiple
states within cells. Under normal conditions, levels of p53 protein are
very low due to rapid turnover. Activation of cellular stress pathways
causes covalent modification and tetramerization of p53, stabilizing the
protein and leading to accumulation within the nucleus. The cellular
outcome depends on the balance of factors present in cells that may
antagonize or promote particular responses.The following promoters are used to target the mammary
gland: the whey acidic protein (WAP) promoter, which is
turned on exclusively during pregnancy and lactation [19];
the mouse mammary tumor virus (MMTV) promoter, which
is expressed constitutively in the mammary gland at low
levels but also in a limited number of other tissues, includ-
ing the salivary gland, and which is responsive to hor-
mones [19]; and the human keratin 14 (K14) gene
promoter, which is expressed in the epithelium of numer-
ous tissues including the mammary gland and skin [21].
While K14 is expressed in myoepithelial cells and rarely in
luminal epithelial cells of the mammary gland, expression
of Cre under the K14 promotor resulted in lacZ reporter
gene expression in both luminal and myoepithelial cells,
possibly due to K14 promotor activity in a common prog-
enitor [21]. It must be noted that promotors used to
express recombinases may result in permanent genetic
changes to cells that only transiently express the recombi-
nase. Promotors must thus be carefully chosen consider-
ing their activity throughout development, not just in the
adult tissue types.
While a molecular approach is one way to target modifica-
tions to the mammary gland, transplantation of mammary
epithelium into cleared fat pads is a valuable alternative
approach to analyze the effects of gene deletion in the
mammary epithelium [22]. With this technique, the
mammary ductal rudiments of 3-week-old (prepubescent)
mice are surgically removed from the abdominal mammary
glands. This leaves the fat pad ‘cleared’ of mammary
epithelium into which donor epithelium can be placed. As
the mouse matures, the donor epithelium will grow to fill
the mammary gland.
Transplantation of Trp53–/– epithelium in this manner has
demonstrated the role of p53 in protection against
mammary tumor formation in the absence of other trans-
genes [23]. Furthermore, the absence of hormonal
requirements to affect gene deletion or to promote trans-
gene expression means that interactions between hor-
monal factors and the gene deletion can be studied.
Contributions of hormonal simulation to mammary tumori-
genesis in the absence of functional p53 have been
studied in this manner [23,24].
While tissue-specific gene deletion has not been widely
applied to studies of p53 function, overexpression of
exogenous genes (i.e. transgenes) under tissue-specific
promoters has been used to study p53 function in the
mammary gland. p53 is a tetrameric protein, thus protein
from a mutant allele can interact with and disrupt the func-
tion of p53 protein from a wild-type allele in a dominant-
negative manner. This has been elegantly demonstrated in
mice by the breeding of mice transgenic for mutant p53
(Val135) to both wild-type and Trp53–/– mice. The mutant
transgene was able to accelerate tumor development in
wild-type and Trp53+/– mice but had no effect in Trp53–/–
mice, indicating its tumor promotion occurred only through
disruption of wild-type p53 function [25].
Other mutant Trp53  genes have been overexpressed
selectively in the mammary gland under the control of the
WAP promoter. These transgenes contain point mutations
commonly found in TP53 in human tumors, such as the
p53-R172H mutant, which have dominant-negative or
gain-of-function properties, and thus in some ways may
better represent the human situation than complete
absence of gene product [26]. However, the use of the
WAP promoter, which is turned on exclusively during
pregnancy and lactation, requires that the mice go through
at least one and often multiple rounds of pregnancy and
lactation to maintain transgene expression. An alternative
approach is the use of the MMTV promoter that is
expressed constitutively in the mammary gland, but this
promoter is also responsive to hormones. Thus, when
transgenes are driven by WAP or MMTV promoters, it is
not possible to dissect hormonal events that may interact
with p53 function in the mammary gland and affect tumori-
genesis. To date, the MMTV promoter has not been used
to introduce modified p53 genes. However, the MMTV
promoter has been used to drive many mammary onco-
genes that have been studied in combination with the
Trp53– allele, as will be discussed (see Table 3 later).
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Table 1
Genetic alterations of the Trp53 gene in mice
Modification Promoter Pregnancy required Effect References
p53 deficient, Trp53– – No No p53 protein [15–17]
Mutant p53 transgenes
p53-R172H WAP Yes Dominant negative/gain of function [33,40]
p53-R172L WAP Yes Super active p53 [49,50]
WAP, whey acidic protein.Activity of p53 in normal mouse mammary
epithelium
The occurrence of p53 mutations in breast cancer and
the high rate of breast cancer in LFS patients pointed to
an important role for p53 in the breast. Initial studies of
p53-deficient mice (Trp53+/– and Trp53–/–) [15–17] did
not, however, reveal any essential function for p53 in the
mammary gland. The p53-deficient mice did not develop
mammary tumors, and both lactation and involution
appeared normal. A closer examination at the cellular
level of wild-type mice compared with Trp53–/– mice,
however, revealed a role for p53-dependent apoptosis in
the early stages of involution. Removal of pups from the
wild-type lactating gland induced p21WAF1 expression, a
p53 target gene, within 24–48 hours. This expression
was absent in Trp53–/– mice. Correspondingly, involution
in the Trp53–/– mice was delayed when examined in the
early (days 2–5) weaning period [27]. Other workers
have also reported observing fewer apoptotic cells at
day 1 of involution in Trp53–/– mice compared with
control mice [28]. Thus, p53 is important in inducing
mammary epithelial apoptosis in response to a physiologi-
cal stimulus.
The p53 protein is also important in the response of
normal mammary epithelium to DNA damaging agents
such as γ-radiation, but responsiveness is greatly affected
by the hormonal status of the animal. In normal resting
epithelium, whole-body irradiation of mice resulted in
minimal increases in p53-dependent transcription of
p21WAF1 and apoptosis. Treatment of the mouse with
exogenous hormones (pregnant mare serum
gonadotrophin and human chorionic gonadotrophin) prior
to irradiation, however, produced a strong p53 response
[29]. In the physiological setting, this regulation of p53
response by hormones has been demonstrated by the
strong induction of p21WAF1 and apoptosis after irradiation
during pregnancy and weaning, but by lack of response
during lactation and in the virgin state [30]. The absence
of p21WAF1 expression and apoptosis in similarly treated
Trp53–/– animals demonstrated that these processes are
p53 dependent.
This variation in p53 activity in the mammary gland
involves many levels of regulation. The p53 mRNA levels
are altered across developmental phases, suggesting hor-
monal regulation of transcription [27,29]. However, the
virgin gland contains high levels of p53 mRNA and yet
does not produce a p53 response to γ-radiation, indicat-
ing that translational and post-translational regulation are
also important. Expression of antagonists of p53, such as
MDM2, also varies across development stages (Pinkas
and Jerry, unpublished data, 2002). However, this does
not fully explain the variations in p53 activity. The mecha-
nisms through which hormones modulate p53 function are
yet to be determined.
The role of p53 in mammary tumor
development in mouse models
Mammary tumor development in p53-deficient mice
While the original Trp53–/– mice developed normally, they
succumbed to a range of tumors, primarily lymphomas,
within 6 months. Mammary tumors were notably absent
[15,16]. To examine the possibility that early death due to
lymphoma may be obscuring mammary tumor develop-
ment in Trp53–/– mice, BALB/c-Trp53–/– mammary epithe-
lium was transplanted into cleared fat pads of wild-type
hosts. In this model, spontaneous mammary tumors
formed in 60% of outgrowths with a latency of 50 weeks
[18,23], demonstrating that p53 deficiency can promote
mammary tumor formation in mice as well as in humans
(Table 2). The tumors formed were moderately to poorly
differentiated adenocarcinomas with high levels of aneu-
ploidy. The long latency and incomplete penetrance of the
phenotype, however, indicated that other genetic events
must be required in addition to the loss of p53 for tumors
to form.
Trp53+/– mice survived much longer than Trp53–/– mice.
They also succumbed to lymphomas and sarcomas,
however, with mammary tumors accounting for less than
1% of tumors in 129/Sv and C57BL/6 x 129/Sv mouse
strains [31]. In contrast, when the Trp53– allele was back-
crossed onto the BALB/c strain (nine generations), which
is known to be more susceptible to mammary tumorigen-
esis, spontaneous mammary tumors occurred in 55% of
Trp53+/– female mice [18]. Genetic components cooper-
ating with p53 deficiency must thus be present in BALB/c
to promote mammary tumor formation, and BALB/c-
Trp53+/– mice may serve as a unique model of LFS [18].
Similar to the Trp53–/– transplant tumors, these tumors
were primarily adenocarcinomas, had a long latency of
8–14 months, and the majority were aneuploid. Further-
more, loss of the wild-type allele of Trp53 occurred in all
mammary tumors examined, suggesting that this is an
important collaborating genetic event in tumor formation
[18]. This is similar to observations in LFS, where loss of
heterozygosity for TP53 occurred at a high rate in breast
cancers [32].
Studies using variations of these two models have
explored the interactions between p53 and hormones, the
mammary carcinogen 7,12-dimethylbenz[a]anthracene
(DMBA), and γ-radiation in mammary tumorigenesis
(Table 2). The Trp53–/– transplant model has been used to
examine the interactions between hormonal stimulation
and p53 deficiency in mammary tumorigenesis. Chronic
hormonal stimulation in the form of pituitary isografts
increased tumor incidence from 60 to 100%, in addition
to decreasing the latency (50 to 37 weeks) [23]. This
observation indicates that, in the absence of p53, hor-
monal stimulation is a very potent tumorigenic stimulus.
Indeed, further investigation has shown that low doses of
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in morphologically normal Trp53–/– mammary epithelial
transplants [24].
Cooperation of the chemical carcinogen DMBA with p53
mutation or p53 deficiency has also been demonstrated in
several situations. DMBA treatment alone decreased
tumor latency (50 to 35 weeks) in Trp53–/– outgrowths
[23]. When administered in addition to hormonal stimula-
tion, latency was further reduced (25 weeks). Cooperation
was also observed in mice carrying the p53-R172H trans-
gene. This transgene, with continuous breeding to
promote expression from the WAP promoter, resulted in
only 10–15% spontaneous mammary tumor incidence in
mice older than 1 year. However, using pituitary isografts
to stimulate maximal transgene expression, the presence
of the mutant p53-R172H transgene increased the tumor
burden and incidence, and decreased the latency of
tumors induced by DMBA administration [33]. A trend
towards cooperation between Trp53+/– and DMBA treat-
ment with pituitary stimulation has also been reported by
Jerry  et al. [34], but it was not statistically significant
(Table 2).
Similar to spontaneous mammary tumor formation, the
ability of γ-radiation to promote mammary tumorigenesis in
Trp53+/– mice is greatly affected by the mouse strain
background. With the Trp53– allele backcrossed one to
six generations onto either the DBA/2 or BALB/c strain,
γ-radiation significantly increased the incidence of
mammary tumors in the BALB/c-Trp53+/– mice but not in
the DBA/2-Trp53+/– mice [35]. This reinforces the impor-
tance of modifier genes that can alter phenotypes of tumor
susceptibility mutations such as Trp53–.
Loss of p53 function is critical in Brca1-associated and
Brca2-associated breast cancer
In addition to LFS, the identification of the two breast
cancer susceptibility genes, BRCA1 and BRCA2, has led
to many efforts to mimic in mice the susceptibility to
breast cancer in humans incurred by mutations in these
genes, and to understand the mechanisms by which they
contribute to mammary carcinogenesis. Towards this, five
strains of Brca1  knockout mice have been generated
(reviewed in [36]), revealing that complete Brca1 defi-
ciency results in embryonic lethality. Brca1+/– mice devel-
oped normally but, unlike humans carrying BRCA1
mutations, failed to show increased susceptibility to
mammary carcinomas, reminiscent of p53 heterozygous
mice and LFS.
Using mice with germline mutations, Cressman et al.
demonstrated cooperativity between p53 and Brca1 in
mammary tumor formation (Table 3), with 10% of
Available online http://breast-cancer-research.com/content/4/3/101
Table 2
p53 deficiency and mutation mammary tumor phenotypes
Model Agent Incidence (%) Latency Loss of heterozygosity References
Trp53–/– Death from nonmammary tumors [15,16,18]
BALB/c mammary epithelium transplants
Trp53+/+ NT or Pit Stim 0 – [23]
Trp53–/– NT 61 50 weeks [18,23]
Trp53–/– Pit Stim 100 37 weeks [23]
Trp53+/+ DMBA 4 26 weeks [23]
Trp53–/– DMBA 60 35 weeks [23]
Trp53+/+ Pit Stim + DMBA 14 27 weeks [23]
Trp53–/– Pit Stim + DMBA 90 25 weeks [23]
Transgenic FVB WAP-p53-R172H mice
p53-R172H Pregnancy 10–15 > 1 year [33]
Wild type Pit Stim + DMBA 85 33 weeks [33]
p53-R172H Pit Stim + DMBA 100 24 weeks [33]
Trp53+/–
B6x129 Trp53+/+ Pit Stim + DMBA 35 5.0 months [34]
B6x129 Trp53+/– Pit Stim + DMBA 40 4.6 months No [34]
BALB/c (N9) Trp53+/– Spontaneous 55 8–14 months Yes [18]
BALB/c or DBA/2 Trp53+/+ γ-Radiation 0 – [35]
DBA/2 (N1-6) Trp53+/– γ-Radiation 6 Yes [35]
BALB/c (N1-6) Trp53+/– γ-Radiation 41 Yes [35]
DMBA, 7,12-dimethylbenz[a]anthracene; NT, no treatment; Pit Stim, hormonal stimulation provided by pituitary isografts; WAP, whey acidic protein.Brca1+/–Trp53–/– mice developing mammary carcinomas
compared with 0% of Brca1+/–Trp53+/+ mice [37]. With
the development of conditional knockouts, Xu et al. were
able to demonstrate more elegantly and sensitively the
cooperation between these two genes. In mice with one
germline and one conditional mutant allele of Brca1
(Brca1Ko/CoMMTV-Cre), mammary tumors developed after
approximately 1 year. The addition of one germline muta-
tion in Trp53 (Brca1Ko/CoMMTV-CreTrp53+/–) accelerated
mammary tumor formation to 6–8 months, and most of
these tumors showed loss of the wild-type allele of Trp53
[38]. Mutations in Brca1  and  Trp53  are thus strongly
cooperative in mammary tumorigenesis.
The first attempts to study Brca2 knockout mice similarly
found that the mutation was embryonic lethal. The recent
generation of conditional Brca2  knockout mice using
K14 promoter-driven Cre expression, however, has
allowed the study of Brca2 deficiency in the mammary
gland [21]. Strikingly, K14cre;Brca2Co/Co females devel-
oped no epithelial tumors over 900 days of monitoring,
but the absence of p53 (also conditionally knocked out)
resulted in all mice developing either skin or mammary
carcinomas by 300 days of age. Deficiency of one Trp53
allele was sufficient to promote mammary and skin tumor
formation, and all tumors had lost the wild-type allele of
Trp53. Disruption of the p53 pathway is thus pivotal in
Brca2-associated breast cancer in mice [21]. This is
consistent with human breast cancer, where mutations in
p53 are seen in a large proportion of BRCA1  and
BRCA2 breast cancers [5,6]. Interestingly, the majority
of the mammary tumors observed in the
K14cre;Brca2Co/CoTrp53Co/Co model were carcinomas
with basal or myoepithelial cell types, perhaps reflecting
the dominant pattern of expression of the K14 promotor
in myoepithelial cells [21].
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Table 3
Cooperation of p53 with other transgenes in mammary tumorigenesis
Mammary tumor
Transgene Trp53 genotype Occurrence Latency Tumor Trp53 status Features References
Brca1+/– +/+ No [37]
–/– 10% [37]
Brca1Ko/Co +/+ Yes 10–13 months Mutations [38]
+/- Accelerated 6–8 months 80% LOH [38]
Brca2Co/Co +/+ No [21]
+/– Yes 360 days 100% LOH [21]
–/– Accelerated 181 days [21]
MMTV-neu Wild type Yes 234 days Mutations Euploid [40]
R172H Accelerated 154 days Aneuploid [40]
WAP-DES Wild type Yes 21 months Euploid [41]
R172H Accelerated 14 months Aneuploid [41]
MMTV-Wnt1 +/+ Yes 22.5 weeks Euploid [42]
+/– Yes (no acceleration) 23.0 weeks 50% LOH [42]
–/– Accelerated 11.5 weeks Aneuploid, ↑ proliferation [42]
Less differentiated [47]
MMTV-ras +/+ Yes, and salivary tumors 8.5 months No mutations [43]
+/– Accelerated 6.3 months No LOH, no mutations [43]
–/– Few ↑ Aneuploidy, ↑ proliferation [43]
Salivary tumors dominate [43] 
MMTV/c-myc +/+ Yes Aneuploid [51]
+/– Few 25% LOH Aneuploid [51]
+/– Lymphomas dominate 90% LOH [51]
LOH, loss of heterozygosity; MMTV, mouse mammary tumor virus; WAP, whey acidic protein; WAP-DES = WAP-des(1–3)insulin-like growth
factor-I transgene.p53 cooperates with many pathways involved in
mammary tumorigenesis
In addition to breast cancer susceptibility genes, p53 has
been studied for cooperativity with pathways activated in
sporadic breast cancer. Transgenic mice overexpressing
oncogenes involved in human breast cancer, such as
HER-2/Neu, Wnt1 and c-myc, have been generated that
develop a high incidence of sporadic mammary carcino-
mas. By crossing these mice with Trp53 mutant mice or
null mice to generate double-transgenic mice, it has been
possible to directly demonstrate pathway cooperativity
(Table 3). For example, HER-2, a member of the epidermal
growth factor receptor family, is overexpressed in approxi-
mately 20% of human breast cancers and is associated
with a poor prognosis [39].
Transgenic mice expressing wild-type rat neu under the
MMTV promoter (MMTV-neu) develop mammary tumors
with an average latency of 234 days that have a high fre-
quency of missense mutations in Trp53 [40]. The cooper-
ativity between the Neu and p53 pathways was clearly
demonstrated by introducing the mutant p53 transgene,
p53-R172H, into these mice, which reduced tumor
latency to 154 days [40]. This study in transgenic mice
has thus demonstrated strong cooperativity between two
genetic lesions common in human breast cancer, and has
demonstrated that p53 mutation is an important event in
Neu-mediated oncogenesis.
Similar cooperativity was observed between p53 and the
insulin-like growth factor pathway. Mice overexpressing
an insulin-like growth factor-I analog, the WAP-
des(1–3)IGF-I transgene (WAP-DES), demonstrated an
80% mammary tumor incidence with a latency of
21 months. This is accelerated to only 14 months when
combined with the mutant p53 transgene p53-R172H
[41]. Cooperativity between p53 and the Wnt pathway
was examined with the Trp53– allele. Female mice trans-
genic for the Wnt1 mammary oncogene develop
mammary tumors with a median latency of 23 weeks.
Inheritance of a single defective allele of Trp53 did not
confer any increased susceptibility in this model, but the
latency was halved to 11.5 weeks with two germline
Trp53– alleles [42]. In MMTV-ras mice, which develop
both mammary tumors and salivary tumors, being
Trp53+/– decreased tumor latency from 8.5 to 6.3 months
with little change in the tumor spectrum [43].
In addition to decreasing tumor latency, defects in the p53
pathway in the aforementioned models altered the histo-
logical grade of the mammary tumors. While the neu
tumors were euploid, neu/p53-R172H bitransgenic
tumors were of a higher histological grade and exhibited
aneuploidy [40]. WAP-DES/p53-R172H bitransgenic
tumors showed a higher proportion of tumors with aneu-
ploidy, and in those tumors they showed a higher propor-
tion of aneuploid cells than in WAP-DES transgenic
tumors [41]. Similar changes were observed in both sali-
vary and mammary tumors of the MMTV-ras with loss of
p53 [43]. In the Wnt1 model, mammary tumors lacking
p53 showed increased genomic instability with aneu-
ploidy, amplifications, and deletions as shown by karyo-
type analysis and comparative genomic hybridization [42].
A common feature of mammary tumors lacking functional
p53, regardless of the driving oncogenic force, is there-
fore genomic instability, which is consistent with the
profile of p53 as ‘guardian of the genome’.
The p53 genotype also affects the tumor growth rate in
several of these models. Mammary tumors from
Wnt1/Trp53–/– mice show more rapid growth once
established compared with Wnt1 tumors with functional
p53. This was not due to decreased apoptosis, as there
was no effect of p53 genotype on apoptosis levels.
However,  Trp53–/– tumors contained more mitotic
figures and had more cells in the S phase than did Wnt1
tumors suggesting elevated proliferation rates as an
underlying defect [44]. Higher rates of proliferation were
also observed in MMTV-ras/Trp53–/– bitransgenic tumors
compared to MMTV-ras alone with no alteration in apop-
tosis levels [43]. This contrasts with animal model
studies in other tissues, where accelerated tumor growth
due to p53 loss occurred primarily through loss of
normal apoptotic function [45,46]. The mechanisms by
which p53 loss influences tumor progression may thus
differ depending on tissue type and/or the oncogenic
pathways involved.
The mechanism by which p53 inhibits tumor growth in the
Wnt1 model has been investigated. Expression profiling of
Wnt1 and Wnt1/Trp53–/– mammary tumors demonstrated
that Trp53–/– tumors showed altered expression of several
proliferation regulatory genes. Expression of p21WAF1
[47], a p53 target gene, was decreased in tumors from
Wnt1/Trp53–/– mice compared to Wnt1 mice. Consistent
with this pathway, Wnt1/p21WAF1+/– mammary tumors dis-
played increased tumor growth rates compared with Wnt1
tumors [48]. The inhibition of tumor growth by p53 may
thus be mediated by p21WAF1.
While some effects of p53 on tumor phenotype have been
clearly identified, the mechanisms by which p53 protects
against cancer in normal mammary glands are more diffi-
cult to elucidate. A ‘superactive’ mutant p53 transgene,
p53-R172L, expressed under the WAP promoter results
in elevated apoptosis rates in normal mammary glands
[49,50]. Interestingly, this transgene delayed mammary
tumor onset induced by DMBA [50] and in transgenic
mice expressing transforming growth factor α [26]. In
these models, protection against breast cancer by p53
may thus be due to removal of genetically damaged cells
by p53-dependent apoptosis.
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showed no alteration in apoptosis rates with Trp53 geno-
type [44], suggesting that p53-mediated apoptosis is not
involved in tumor prevention in this model. Furthermore, in
this same model, deficiency in p21WAF1 (Wnt1/p21WAF1–/–
and  Wnt1/p21WAF1+/– mice) was unable to mimic the
acceleration due to loss of p53 [48]. In the Wnt1 model,
therefore, it appears that protection against tumorigenesis
by p53 occurs through mechanisms other than apoptosis
or p21WAF1-mediated cell-cycle arrest, such as maintain-
ing genomic stability.
While p53 cooperates with many models, this is not the
case in all models. Female mice carrying the MMTV/c-myc
transgene develop mammary carcinomas at 8–10 months
of age, with occasional lymphomas developing in males.
When only one p53 allele is present, however, mice
develop aggressive lymphomas that appear to require loss
of the wild-type allele of p53. In contrast, there was no
sign of acceleration of mammary tumors, and three-quar-
ters of the mammary tumors that did form had retained the
wild-type allele [51], indicating that cooperativity between
c-myc and p53 is dependent on tissue type. Regardless of
p53 genotype, c-myc tumors showed changes in ploidy
and chromosomal aberrations [52]. The lack of tumor
acceleration in the presence of c-myc-induced chromoso-
mal instability and the lack of a role for apoptosis and
p21WAF1 cell-cycle arrest in the Wnt1 model suggest that
maintenance of genomic stability may be a major role for
p53 in the prevention of mammary tumors.
SV40 viral oncogene inactivation of p53
The function of p53 protein may also be abrogated by
expression of the SV40 viral oncogenes. While these viral
proteins are not involved in human breast cancer, the viral
proteins mimic alterations etiologically linked with human
breast cancer. For this reason, several transgenic mice
have been generated for studying mammary tumorigenesis
[53–57]. However, there are several complications with
these models in terms of understanding p53 function in
breast cancer.
The first SV40 transgenics contained the SV40 early
region, which produces multiple gene products including
the large T antigen that functionally inactivates both pRb
and p53, and including the small t antigen that inhibits the
serine/threonine phosphatase PP2A. These models there-
fore do more than just interfere with p53 function, and it is
only recently that the contribution of the different compo-
nents of these gene products has been fully investigated.
A recent study by Goetz et al. [58] generated several
WAP-SV40 transgenic lines that produce either large T
antigen only (WAP-SVT), small t antigen only (WAP-SVt),
or N-terminal truncated large T antigens (WAP-SVBst-
Bam). All of these lines developed mammary tumors with a
lower incidence than the original mice expressing both
large T and small t antigens (SVT/t) (100, 64, 6–12 and
0% for SVT/t, SVT, SVt and SVBst-Bam, respectively)
[57,58], indicating many cooperating functions in the SV40
early genome. Of particular note, however, is the lack of
mammary tumors due to the SVBst-Bam transgene that
retains the recognized pRb-binding and p53-binding por-
tions of the SV40 genome. In contrast, small t antigen
alone was able to result in tumor formation. The p53 and
pRb binding activities of large T antigen thus require coop-
eration with small t antigen and the N-terminal region of
large T antigen to induce mammary tumor formation [58].
p53 and metastases, chemotherapy and gene
therapy
Most mouse models of breast cancer do not display
metastatic disease. However, mice expressing the SV40
early genome under the control of the C3(1) component
of the rat prostatic steroid binding protein promoter
(C3(1)/TAG) [56] develop very aggressive mammary
tumors in only 16 weeks, with around 15% showing lung
metastases.
In this model, mice being Trp53+/– did not significantly alter
latency or lead to loss of the remaining allele of Trp53. It
did, however, result in more aggressive mammary tumors,
as evidenced by increased numbers and sizes of metas-
tases, than did TAG-Trp53+/+ mice [59]. Thus, loss of p53
results in higher grade tumors, more aneuploidy in the
primary tumor and promotes metastases. This is consistent
with the poorer prognosis of patients with p53-
negative/mutated tumors versus those without p53 muta-
tions. The protection against metastases by p53 may be
mediated by its induction of anti-angiogenesis genes, but
these characteristics of p53 have not been fully explored in
the transgenic/knockout mouse models to date.
The widely held tenet of chemotherapy is that cells die
due to apoptosis, and that the absence of p53 may result
in resistance to apoptosis and hence to chemotherapy.
However, this has not been demonstrated clearly for non-
hematological tumors [60]. Indeed, the p53-mediated
apoptotic response to γ-radiation of mouse tumors was
shown to vary among tissues [61]. In DMBA-induced
mouse mammary tumors, whole-body irradiation was able
to induce nuclear p53 expression and apoptosis. This
contrasted other tumor types, such as liver and lung ade-
nomas, where neither p53 expression nor apoptosis was
induced by radiation. Thus, while the role of p53 in induc-
ing apoptosis in response to radiation (and probably other
chemotherapeutic agents) varies among tissue and tumor
types, it would appear that mammary tumors retaining
wild-type p53 are one type in which p53 is important [61].
Barrington et al. [62] have made use of transgenic mouse
models to examine the role of p53-mediated apoptosis in
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agents. L-744,832, a potent and selective inhibitor of far-
nesyltransferase that catalyses an obligatory step in Ras
protein activation, leads to the rapid regression of
mammary and salivary tumors in MMTV-ras transgenic
mice. This occurred by inducing high levels of apoptosis,
and tumors arising in ras/Trp53–/– mice regressed at least
as efficiently as ras/Trp53+/+ mouse tumors, indicating
that the response was largely p53-independent [62]. This
contrasts with the effectiveness on ras/Trp53–/– salivary
tumors of doxorubicin, which was not able to inhibit tumor
growth, and of paclitaxel, which inhibited growth but did
not result in regression [63]. Yet both these agents were
effective in ras/Trp53+/+ tumors. Interestingly, neither dox-
orubicin nor paclitaxel efficiently induced apoptosis but,
rather, they changed the distribution of cells in the cell
cycle. The p53 knockout and transgenic models can thus
be used to examine mechanisms and effectiveness of ther-
apeutic agents in the presence and absence of p53. The
use of mouse models in this way will probably provide valu-
able information for the clinic on the tailoring of therapeutic
agents that target particular molecular lesions of cancers.
In addition to altering the cell cycle and apoptosis as a
means of mediating treatment efficacy, the expression of
p53 in mammary tumors can also alter the efficacy of
immunomodulatory gene therapy. In mice bearing PyMT-
induced tumors, intratumoral injection of adenoviruses car-
rying either IL-2 or p53 was able to delay tumor growth,
but when treated with both viruses together, regression in
65% of tumors without IL-2 toxicity was obtained [64].
The mechanisms by which p53 enhances this treatment
are unclear, but may be due to growth inhibition allowing
expansion of the cytotoxic T-lymphocyte response towards
the tumors. Only a small percentage of tumor cells in this
system are infected by the adenovirus, so while the anti-
tumor growth may be mediated by apoptosis, it is likely to
also involve a large bystander effect, and perhaps anti-
angiogenesis mechanisms [64].
Conclusions
While initial studies of Trp53  knockout mice did not
suggest that p53 was important in the mouse mammary
gland, it is now clear that p53 has important roles in
normal physiology and tumorigenesis in the mouse.
Knockout and transgenic mice with modified p53 func-
tions will thus be useful tools in understanding breast
cancer biology and response to therapies. p53 can
mediate apoptosis in the mammary gland in response to
both physiological and exogenous stresses. Deficiency of
p53 alone, in a susceptible genetic setting, is sufficient to
allow mammary tumor development in mice, and it has
also been demonstrated to be pivotal in breast cancer for-
mation in the context of Brca1 and Brca2 deficiency. We
are therefore now able to model in mice three strong
breast cancer susceptibility syndromes of humans.
Deficiency of p53 modifies tumor biology, promoting
aggressiveness, rapid growth and genetic instability. p53
deficiency in the mouse cooperates with other oncogenic
events important to human breast cancer, accelerating
mammary tumor formation. Identification of further path-
ways (and hence modifier genes) with which p53 defi-
ciency cooperates, combined with understanding
mechanisms that regulate p53 activity, will greatly
enhance our understanding of breast cancer biology and
our ability to prevent it. With the complexity of tumor
biology and the paracrine activities of p53, such as anti-
angiogenic activities, the use of p53 transgenic and
knockout mice provides important in vivo tools for under-
standing and developing therapeutic strategies.
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